Roche: kidney cancer combo linked to lower risk of death
(CercleFinance.com) - Roche's Tecentriq and Avastin reduced the risk of disease worsening or death by 26% in certain people with advanced kidney cancer, a Phase III study showed on Tuesday.
The Swiss drugmaker now plans to present this positive data at the upcoming Genitourinary Cancers Symposium on Saturday 10 February and to enter into related discussions with global health authorities, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
However, some analysts say this may not look "as good as it seems."
"So far, our impression is that Tecentriq is involved in a lot of trials of various tumour types resulting usually in positive outcomes but never with a best-in-class status," Bryan Garnier warns in a report this morning.
The Roche share was managing to contain its losses in Zurich, down just 0.4% at 221.1 Swiss francs, while the Swiss SMI index was down 1.6%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Swiss drugmaker now plans to present this positive data at the upcoming Genitourinary Cancers Symposium on Saturday 10 February and to enter into related discussions with global health authorities, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
However, some analysts say this may not look "as good as it seems."
"So far, our impression is that Tecentriq is involved in a lot of trials of various tumour types resulting usually in positive outcomes but never with a best-in-class status," Bryan Garnier warns in a report this morning.
The Roche share was managing to contain its losses in Zurich, down just 0.4% at 221.1 Swiss francs, while the Swiss SMI index was down 1.6%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.